Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations
Cell Metabolism · 2023-09 · 35 (9) · 1530-1547.e8
DOI: 10.1016/j.cmet.2023.08.002 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cell Metabolism, 2023-09. Verfasst von Yueqiong Ni und 24 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Key Laboratory of Diabetes Mellitus, Department of Endocrinology and Metabolism, Shanghai Diabetes Institute, Shanghai Clinical Center for D…. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Microbiota, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 225-mal zitiert (Crossref) und nennt 72 Literaturangaben. Gefördert von: Innovative Research Team of High-level Local University in Shanghai, National Key Research and Development Program of China, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Non-alcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic dysfunction for which effective interventions are lacking. To investigate the effects of resistant starch (RS) as a microbiota-directed dietary supplement for NAFLD treatment, we coupled a 4-month randomized placebo-controlled clinical trial in individuals with NAFLD (ChiCTR-IOR-15007519) with metagenomics and metabolomics analysis. Relative to the control (n = 97), the RS intervention (n = 99) resulted in a 9.08% absolute reduction of intrahepatic triglyceride content (IHTC), which was 5.89% after adjusting for weight loss. Serum branched-chain amino acids (BCAAs) and gut microbial species, in particular Bacteroides stercoris, significantly correlated with IHTC and liver enzymes and were reduced by RS. Multi-omics integrative analyses revealed the interplay among gut microbiota changes, BCAA availability, and hepatic steatosis, with causality supported by fecal microbiota transplantation and monocolonization in mice. Thus, RS dietary supplementation might be a strategy for managing NAFLD by altering gut microbiota composition and functionality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Key Laboratory of Diabetes Mellitus, Department of Endocrinology and Metabolism, Shanghai Diabetes Institute, Shanghai Clinical Center for Diabetes, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao…
- Microbiome Dynamics, Leibniz Institute for Natural Product Research and Infection Biology - Hans Knöll Institute, Beutenbergstraße 11A, 07745 Jena, Germany.
- State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, China; Department of Medicine, The University of Hong Kong, Hong Kong, China.
- Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio 70211, Finland; School of Biological Sciences, Faculty of Science, The University of Hong Kong, Hong Kong SAR, China.
- College of Food Science and Technology, Shanghai Ocean University, Shanghai 201306, China.
- CAS Key Laboratory of Separation Science for Analytical Chemistry, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China.
Förderung
- Innovative Research Team of High-level Local University in Shanghai
- National Key Research and Development Program of China
- Deutsche Forschungsgemeinschaft
- National Natural Science Foundation of China
- Chinese Academy of Sciences
- Dalian Institute of Chemical Physics, Chinese Academy of Sciences
- H2020 Marie Skłodowska-Curie Actions
- School of Medicine, Shanghai Jiao Tong University
Zitieren
APA
Ni, Y., Qian, L., Siliceo, S. L., Long, X., Nychas, E., Liu, Y., Ismaiah, M. J., Leung, H., Zhang, L., Gao, Q., Wu, Q., Zhang, Y., Jia, X., Liu, S., Yuan, R., Zhou, L., Wang, X., Li, Q., Zhao, Y., …, & Jia, W. (2023). Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations. Cell Metabolism, 35(9), 1530-1547.e8. https://doi.org/10.1016/j.cmet.2023.08.002
Vancouver
Ni Y, Qian L, Siliceo SL, Long X, Nychas E, Liu Y, et al. Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations. Cell Metabolism. 2023;35(9):1530-1547.e8. doi:10.1016/j.cmet.2023.08.002
BibTeX
@article{Ni2023,
author = {Ni, Yueqiong and Qian, Lingling and Siliceo, Sara Leal and Long, Xiaoxue and Nychas, Emmanouil and Liu, Yan and Ismaiah, Marsena Jasiel and Leung, Howell and Zhang, Lei and Gao, Qiongmei and Wu, Qian and Zhang, Ying and Jia, Xi and Liu, Shuangbo and Yuan, Rui and Zhou, Lina and Wang, Xiaolin and Li, Qi and Zhao, Yueliang and El-Nezami, Hani and Xu, Aimin and Xu, Guowang and Li, Huating and Panagiotou, Gianni and Jia, Weiping},
title = {Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations},
journal = {Cell Metabolism},
year = {2023},
volume = {35},
number = {9},
pages = {1530--1547.e8},
doi = {10.1016/j.cmet.2023.08.002}
}
EUVIMED